Know Cancer

or
forgot password

Retrospective Analysis Evaluating Molecular Factors of Primary Resistance to Tyrosine Kinase Inhibitors in Metastatic Non Small Cell Lung Cancer Patients


N/A
18 Years
N/A
Open (Enrolling)
Both
Non Small Cell Lung Cancer

Thank you

Trial Information

Retrospective Analysis Evaluating Molecular Factors of Primary Resistance to Tyrosine Kinase Inhibitors in Metastatic Non Small Cell Lung Cancer Patients


Non small cell lung cancer patients.


Inclusion Criteria:



- Histologically confirmed diagnosis of NSCLC (non small cell lung cancer) with
available tumor tissue for mutational analysis

- Metastatic disease treated with gefitinib or erlotinib

- Presence of at least one measurable lesion according to RECIST criteria

Exclusion Criteria:

- No tumor tissue available

- No clinical data available

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Retrospective

Outcome Measure:

Determine the incidence of EGFR (Epidermal growth factor ) and KRAS (Kirsten ras sarcoma viral oncogene homolog ) mutations in 300 NSCLC (non small cell lung cancer) patients treated with gefitinib or erlotinib

Outcome Time Frame:

1 year

Safety Issue:

No

Principal Investigator

Armando Santoro, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Istituto Clinico Humanitas

Authority:

Italy: Ministry of Health

Study ID:

ONC/OSS-01/2010

NCT ID:

NCT01163058

Start Date:

June 2010

Completion Date:

July 2011

Related Keywords:

  • Non Small Cell Lung Cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location